New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
09:14 EDTMDGNHouse Energy & Commerce Committee to hold a hearing
The Subcommittee on Health holds a hearing entitled, "21st Century Cures: The Presidentís Council of Advisors on Science and Technology (PCAST) Report on Drug Innovation" with EVP Sara Radcliffe of Biotech Industry Organization and Dr. Garry Neil of Medgenics on May 20 at 10 am. Webcast Link
News For MDGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
10:19 EDTMDGNSpark trial success a positive for gene therapy sector, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he views the news that Spark Therapeutics (ONCE) "highly anticipated" SPK-RPE65 Phase 3 gene therapy study for congenital blindness met its primary endpoint as a positive for the ophthalmology gene therapy field as well as the broader gene therapy sector. Schimmer added that Applied Genetic Technologies' (AGTC) early clinical data in the second half of this year will be a further test of the ophthalmology gene therapy platform. The analyst noted that other companies with gene therapy programs include Avalanche (AAVL), Biogen (BIIB), bluebird bio (BLUE), BioMarin (BMRN), Cellectis (CLLS), Medgenics (MDGN), uniQure (QURE), Pfizer (PFE), Regeneron (REGN) and Sangamo (SGMO).
October 1, 2015
09:00 EDTMDGNMedgenics 6.15M share Spot Secondary priced at $6.50
Subscribe for More Information
September 30, 2015
19:12 EDTMDGNOn The Fly: After Hours Movers
UP AFTER EARNINGS: 8Point3 Energy (CAFD), up 3.2%. ALSO HIGHER: PBF Energy (PBF), up 4.3% after announcing that it will acquire a Torrance, CA refinery from ExxonMobil (XOM)... Verisk Analytics (VRSK), up 5.2% after being added to the S&P 500. LOWER: Medgenics (MDGN), down 11.1% after filing to sell common stock... Concho Resources (CXO), down 4.4% after filing to sell 7M shares of common stock... Joy Global (JOY), down 2.2% after Verisk Analytics replaced the company in the S&P 500... Amicus Therapeutics (FOLD), down 1.7% after filing to sell 5.92M shares of common stock for holders.
16:02 EDTMDGNMedgenics files to sell common stock, no amount given
Piper Jaffray & Co. is acting as sole book-running manager for the proposed offering. JMP Securities LLC is acting as lead manager and Needham & Company, LLC is acting as co-manager.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use